CRDF Cardiff Oncology Inc

$CRDF The last date for data cutoff was March 18. Thus, we are approaching 6 mos later and I would suspect another data cutoff. But looking back at the data from March there were 4 remaining on study in the 30mg study arm with FOLFIRI/bev, but there were 5 that had left for surgery which is also a positive outcome. The FOLFIRI/bev SOC arm positive outcomes were 1 remaining on study with 3 undergoing surgical conversions. (IE, 9 vs 4) Leaving for negative reasons(death or progressive disease) were 4 in the 30mg study arm vs 9 in the FOLFIRI/bev SOC arm. (IE, 4 vs 9). My conclusion is that the data are speaking for their self and that is more essential than the vagaries from lawsuits(resolved) and financial considerations, ie, funding, which will be remedied in view of the positive data. Just my pedestrian thoughts.

$CRDF Regardless of price, we are about to start a phase 3 with a proven cell cycle drug, using the right target; Bev-Naive patients, the right dosage, and soon with the right partner. This is good for patients, cancer therapy, the pharma acquirer, and share holders. Price will catch up soon enough. Buy more shares is my only advice!

$CRDF Oct 21 (Reuters) - Cardiff Oncology, Inc.(CRDF): 👀 💥* CARDIFF ONCOLOGY RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ONVANSERTIB IN CHRONIC MYELOMONOCYTIC LEUKEMIA 💥* CARDIFF ONCOLOGY(CRDF) - ONVANSERTIB BEING EVALUATED IN PHASE 1 STUDY FOR RELAPSED/REFRACTORY CMML 💥* CARDIFF ONCOLOGY(CRDF) - ONVANSERTIB SHOWED PRELIMINARY EFFICACY IN 40% OF MYELOPROLIFERATIVE CMML PATIENTS

$CRDF I just had a short conversation with an oncologist....he mentioned the horrendous toxicities of Rasonque for pancreatic .....he can't believe it was approved they are so bad but they have nothing else....he told me they are now pushing it hard for mCRC and he is starting a 3rd line pt on it...I'm assuming that is off label....I brought up Onva which he was not aware of....he said any drug that extends mPFS by 6 months in first line mCRC would be huge.....also having to use Folfiri with it would present no problem at all and would be immediately adopted

$CRDF there is really nothing much to talk about until they reveal more data and/or partnerships. It’s the waiting game

$CRDF market cap of $72M. Few warrants outstanding. This market cap is not one for a company about to launch into p3 for mCRC. It’s silly in some sense: we are now back to where we were early Jan, if anything better off. Got rid of crazy Erlander. Settled with NMS. Got confirmation of strong results for 30mg arm with folfiri. Got new orphan designation. Finalizing 005 protocol. Will soon announce solid final update on 004. And yet we are at 1/3 valuation to where we were before all the mess. Go figure. I cannot reasonably add more here. But it is mighty tempting. Go Cardiff!

$CRDF Many retail investors here are less patient than when they thought the sky was falling during the NMS negotiations. Partner negotiations take time and skill to get done right. I’m looking for $750 million cash up front with milestone payments up to the amount the acquiring company is willing to pay for Onvansertib across all indications. Prove me wrong!

$CRDF The market's response has been the same at every stage: Stronger data → "Show me randomized data." Randomized data looks good → "Show me a registrational path." Registrational path appears possible → "Resolve the litigation." Litigation gets resolved → "Show me Phase 3." At some point, investors need to ask whether they're evaluating risk or simply pushing value recognition further into the future. Every major milestone reduces uncertainty. Yet the valuation often acts as if none of the prior milestones happened.

$CRDF One of the richest pipelines in Oncology research, as I Always said. One of the most undervalued companies on the board. I only Hope that management Is serious and Will not pursue any kind of Toxic diluition. This Is the only fear.

$CRDF SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc.(CRDF) , a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML). “CMML remains a difficult-to-treat hematologic malignancy with limited treatment options for patients, and 40-50% of myeloproliferative CMML1 patients harbor RAS-pathway mutations, which are associated with more aggressive disease,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology(CRDF). “Receiving Orphan Drug Designation for onvansertib in CMML further validates the therapeutic potential of PLK1 inhibition in cancers with significant unmet need and adds to the growing body of evidence supporting this mechanism across both solid tumors and hematologic malignancies.

$CRDF there’s been mass institutional selling across biotech the past few weeks. If you’re still confident in the data we’ve seen so far and their ability to find a partner then these are the situations to take advantage of

$CRDF In a fit of masochism, I bought a little bit more today at .80 to lower my average. This collapse of the share price following the legal settlement still doesn't make any sense to me.

$CRDF What Mani has actually said At the September 2026 H.C. Wainwright conference, Mani was asked directly how Cardiff intended to finance Phase 3, including strategic partnerships, royalty arrangements and secondary offerings. She said Cardiff was pursuing multiple avenues, including capital markets, non-dilutive financing, regional collaborations and other mechanisms. She also reiterated the goal of starting the global Phase 3 study in Q1 2027, subject to funding. So, we know that Mani is actively looking at non-diluting financing through regional collaboration or licensing that is essential a partnership. I believe that the reason that NMS stepped in and challenged the patent was due to possible partnerships talks between Cardiff executives and other big pharmaceutical companies (may be more that one). This quite period may signal ongoing negotiations to structure the partnership for funding Phase 3 in Q1 2027! Conference transcript provided below

$CRDF While NMS was actively locked in a lawsuit with CRDF at $0.80, bankruptcy was never mentioned. Yet, now that they’ve settled and secured a cash runway extending into Q3 2027, bankruptcy concerns are suddenly emerging. Human logic in the stock market never ceases to amaze me.

$CRDF From someone inside Cowen is all I can say The market assessment is that the clinical package should be sufficient to support serious partnership now or if they were pursuing acquisition negotiations today, without waiting for any Phase 3 results. If they wait till 6 months into the trial, valuation obviously goes up but after needed partner dilution that wait may not be worth the $.

$CRDF pacira was just acquired in which Pace was a director there until 2024. Lets see if lightning strikes twice

$CRDF everyday passing by this gets closer and closer to rvph route.. good asset in wrong hands.. Seems like management has no clue what to do .. while shorts grind them to ground making every damn way of fiinding ph3 financing more difficult as your market cap get to ridiculous levels.

$CRDF I would like to know what mgmt has been doing for 7 months. they lawyers handled the litigation. All they should have been working on is P3 plan and funding. They say they have the plan but they have been doing little on the funding. Seems like a new CFO and/or CEO is needed.

$CRDF .99 Volatility. It’s still one of the very few that’s worth a risk. Will continue to fill my bag as much as I can on this range. This could takeoff in 2 weeks. 🚀

$CRDF market is basically pushing the firm to disclose something, anything. Let’s see if they bite.